Status
Conditions
About
ReLF is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been developed to corroborate and integrate data from different resources and aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.
Full description
The traditional method of collecting patient information is often chaotic, inconvenient, and sometimes even unsafe, particularly when dealing with rare diseases. In 2020, the need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, led to the suggestion of implementing the Registry of Li Fraumeni and Li Fraumeni Like syndromes (ReLF).
The ReLF relies on an IT Platform named GeDI (Genotype-phenotype Data Integration platform). This solution, realized by a collaboration among Department of Rare Skeletal Disorders and a local software-house (Dilaxia Spa), is a GDPR-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphacode, ICD-10, Human Genome Variants Society, Findability Accessibility Interoperability Reusability -FAIR- Principles). GeDI is continuously implemented to improve management of persons with Li Fraumeni and Li Fraumeni Like Syndromes and to help researchers in analyzing collected information. ReLF is articulated in main sections:
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
200 participants in 1 patient group
Loading...
Central trial contact
Marcella Lanza, PhD; Marina Mordenti, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal